Key facts
- This page summarizes Kenneth Allen Myszkowski's Form 4 filing for ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
- 5 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 07 Jan 2025, 21:27.
Kenneth Allen Myszkowski - 04 Jan 2025 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ARWR
- Reported as of
- 04 Jan 2025
- Net transaction value
- -$893,095
- SEC form
- 4
- Accepted by SEC
- 07 Jan 2025, 21:27:58 UTC
- Prior SEC filing
- 08 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/Kenneth Myszkowski
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kenneth Allen Myszkowski filed Form 4 for ARROWHEAD PHARMACEUTICALS, INC. (ARWR) on 07 Jan 2025.
Change
- Previous filing in this sequence was filed on 08 Mar 2024.
- Current net transaction value: -$893,095.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARWR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- +25%
- Price
- $0.000000
- Shares after
- 500,600
- Date
- 04 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
ARWR
transaction
Common Stock
Sale
- Transaction value
- $349,615
- Shares
- -17,765
- Change %
- -3.5%
- Price
- $19.68
- Shares after
- 482,835
- Date
- 06 Jan 2025
- Ownership
- Direct
- Footnotes
- F2, F3, F4, F5
ARWR
transaction
Common Stock
Sale
- Transaction value
- $188,980
- Shares
- -9,402
- Change %
- -1.9%
- Price
- $20.10
- Shares after
- 473,433
- Date
- 06 Jan 2025
- Ownership
- Direct
- Footnotes
- F2, F3, F5, F6
ARWR
transaction
Common Stock
Sale
- Transaction value
- $157,600
- Shares
- -8,000
- Change %
- -1.7%
- Price
- $19.70
- Shares after
- 465,433
- Date
- 07 Jan 2025
- Ownership
- Direct
- Footnotes
- F2, F3, F5, F7
ARWR
transaction
Common Stock
Sale
- Transaction value
- $196,900
- Shares
- -10,000
- Change %
- -2.1%
- Price
- $19.69
- Shares after
- 455,433
- Date
- 07 Jan 2025
- Ownership
- Direct
- Footnotes
- F5, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 8 footnotes
Footnote F1
Represents shares underlying restricted stock units with a grant date 01/04/2025, which will vest in four equal annual installments.
Footnote F2
Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Footnote F3
Partial disposition of RSUs to satisfy tax withholding obligations.
Footnote F4
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.18 to $20.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Footnote F5
Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
Footnote F6
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Footnote F7
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 19.64 to $ 19.79, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Footnote F8
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.62 to $19.78, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.